false
0001509261
0001509261
2024-01-23
2024-01-23
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
January 23, 2024
REZOLUTE, INC.
(Exact Name of Registrant as Specified in Charter)
Nevada |
|
001-39683 |
|
27-3440894 |
(State or Other Jurisdiction
of Incorporation) |
|
(Commission
File Number) |
|
(I.R.S. Employer
Identification No.) |
275 Shoreline Drive, Suite 500, Redwood City,
CA 94065
(Address of Principal Executive Offices, and
Zip Code)
650-206-4507
Registrant’s Telephone Number, Including
Area Code
Not Applicable
(Former Name
or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
|
¨ |
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
¨ |
Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
¨ |
Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
Common Stock, par value $0.001 per share |
RZLT |
Nasdaq Capital Market |
Indicate by check mark
whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this
chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).
Emerging growth company
¨
If an emerging growth
company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 3.02 |
Unregistered Sale of Equity Securities. |
The disclosure contained
in Item 5.02 of this Current Report on Form 8-K regarding the issuance of an inducement grant pursuant to Nasdaq Listing Rule 5635(c)(4)
in the form of stock options to purchase 275,000 shares (the “Inducement Grant”) of Rezolute, Inc. (the “Company”)
common stock to Daron Evans at an exercise price of $1.02, in connection with his employment, is incorporated by reference. The Inducement
Grant is exempt from the registration requirements of the Securities Act of 1933, as amended, by virtue of Section 4(a)(2) thereof and/or
Regulation D promulgated thereunder.
Item 5.02 |
Departures of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
Appointment of Chief
Financial Officer
On
January 23, 2024, the Company’s Board of Directors approved the appointment of Mr. Evans, 50 years of age, to serve as the Company’s
Chief Financial Officer. Prior to joining the Company, he served as Chief Executive Officer of AlloRock, Inc., a biotechnology company
in the cardiometabolic disease space, as well as Chief Executive Officer of Specialty Renal Products, Inc., a medical device company in
the dialysis space. Previously, Mr. Evans served as Chief Executive Officer of Nephros, Inc, and Chief Financial Officer of Nile Therapeutics,
Inc. Since 2015, Mr. Evans has been Managing Director of PoC Capital, LLC, a fund focused on investing in public life science companies.
In
connection with Mr. Evans’ appointment as Chief Financial Officer of the Company, the Company extended Mr. Evans an employment offer
letter (the “Offer Letter”). The Offer Letter provides for the following compensation: (i) an annual base salary of $275,000;
(ii) eligibility to receive an annual performance bonus with a target of 50% of Mr. Evans’ base salary, on December 31st
of each year; and (iii) the Inducement Grant. The stock options issued as the Inducement Grant will vest and become exercisable as to
25% of the underlying shares on the first anniversary of the grant date, and will vest and become exercisable as to the remaining 75%
of the underlying shares in 36 equal monthly installments from the first anniversary of the grant date, subject to his continued employment
with the Company on such vesting dates. If the Company is acquired during his employment, all remaining options will automatically vest.
All
stock awards are subject to recovery to other penalties pursuant to (i) the Company’s clawback policy, as may be adopted or amended
from time to time, or (ii) any applicable law, rule or regulation or applicable stock exchange rule, including, without limitation, Section
304 of the Sarbanes-Oxley Act of 2002, Section 954 of the Dodd-Frank Wall Street Reform and Consumer Protection Act and any applicable
stock exchange listing rule adopted pursuant thereto.
Mr.
Evans will be subject to customary restrictive covenants in the Offer Letter, including nondisclosure of confidential information, nondisparagement
and the return of Company property. The foregoing description of the terms of the Offer Letter is qualified in its entirety by reference
to the Employment Agreement, which is filed as an exhibit to this Current Report on Form 8-K and is incorporated herein by reference.
There are no understandings
or arrangements with any persons regarding the appointment of Mr. Evans to the position of Chief Financial Officer, there are no reportable
related-party transactions with Mr. Evans, and there are no family relationships between him and any other officer or director of the
Company. Additionally, Mr. Evans has not engaged in any transaction with the Company that would
be reportable as a related party transaction under Item 404(a) of Regulation S-K.
Item 7.01 |
Regulation FD Disclosure. |
On January 23, 2024,
the Company issued a press release announcing that the U.K. Medicines and Healthcare products Regulatory Agency has awarded the innovative
medicine designation, the Innovation Passport, to RZ358 for the treatment of hypoglycemia due to congenital hyperinsulinism.
On January 24, 2024,
the Company issued a press release announcing the appointment of Mr. Evans as the Company’s Chief Financial officer.
The information in this
Item 7.01, including Exhibits 99.1 and 99.2, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange
Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed
incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before
or after the date hereof, except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K.
Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
REZOLUTE, INC. |
|
|
|
|
|
|
DATE: January 29, 2024 |
By: |
/s/ Nevan Charles Elam |
|
|
Nevan Charles Elam |
|
|
Chief Executive Officer |
Exhibit 10.1
January 23, 2024
VIA EMAIL:
Dear Daron:
We are very excited to offer you the position
of Chief Financial Officer, at Rezolute, Inc., a Nevada corporation (“Company”). If you accept this offer, your first
day of employment will be today, January 23, 2024 (“Effective Date”) and you will report to Nevan Elam, Chief Executive
Officer.
Additional terms of your employment are more fully
described below in this letter (“Letter”).
1. Status
and Term. You will be a full-time, “at-will” employee of the Company and your employment is not for a specified term,
which means that you or the Company is free to terminate the employment relationship at any time, for any reason.
2. Location.
Your principal place of work will be the Rezolute, Inc. office in Redwood City, CA. You will be expected to be flexible with your
work hours and travel as required to fulfill your work duties.
3. Compensation
and Benefits. As compensation for your services, you will be entitled to the following compensation and benefits:
(a) Base
Salary. From the Effective Date, the Company shall pay you a base salary of Two Hundred Seventy-Five Thousand ($275,000) per annum
(“Base Salary”), payable in accordance with the Company’s payroll practices, but no less than once a month.
(b) Bonus
Compensation. You will be eligible to receive an annual performance bonus of up to Fifty (50%) of your base salary. Determination
of the actual bonus amount shall be based on the Company’s performance as well as your individual performance for the year. Your
discretionary bonus, if any, will be earned on December 31st of each calendar year. In order to remain eligible to receive
an annual performance bonus, you must continue to be employed by the Company, in good standing, through the date that the bonus is paid.
Notwithstanding anything herein to the contrary, subsequent to the approval of the board of directors, any bonus amount due to you will
be paid within the first quarter of the year following the date that the bonus was earned.
(c) Long
Term Incentives. Through the term of your employment, you will be eligible to receive awards under Rezolute’s Equity Incentive
Plans (pursuant to the terms and conditions of the plans) as determined by the board of directors in its sole discretion.
In addition, as an inducement to the commencement of your
employment, today the board of directors approved an initial grant of stock options as outlined below, which are intended to constitute
“employment inducement” awards under Nasdaq Rule 5635(c)(4) (“Inducement Awards”). The Inducement Awards
are subject to the terms of an award agreement between you and Rezolute.
|
|
|
|
|
|
|
|
|
|
|
|
|
Effective
Grant Date |
|
Type
of Award |
|
Number of Shares
Subject to the Award |
|
|
Exercise
Price |
|
|
Vesting Period |
January 23, 2024 |
|
Stock Option |
|
|
275,000 |
|
|
|
$1.02 |
|
|
Four year vesting with a one year cliff |
You will receive formal award agreements and additional information
regarding your award over the coming weeks. With respect to your Inducement Awards, in the event that there is a Change in Control Event
(as defined below) and within 12 months of such event, your employment is terminated (i) by
the Company without cause or (ii) by you with Good Reason (as defined below), then all of the stock options granted as part of the
Inducement Awards shall accelerate and become exercisable for a period of 90 days from the date of your last day of employment with the
Company.
(d) Tracking-Free
Vacation. Rezolute, Inc. is striving to build a results-driven culture that enables our employees to flexibly manage their vacation
time. Through our tracking-free vacation (“TFV”) program, employees, working closely with their manager, can set their vacation
schedules so that the employee’s goals and objectives, as well as their time away to refresh and relax, are built into their annual
plan. Additional information on our TFV program can be found in the Employee Handbook Addendum.
(e) Insurance
Coverage. During the term hereof, the Company shall provide you with medical, dental, vision, life and disability insurance in accordance
with the Company’s policies which will be separately furnished to you.
(f) 401k
Retirement Plan. During the term hereof, you shall be entitled to participate in the Company’s 401k retirement plan.
(g) Other
Benefits. During the term hereof and subject to any contribution therefor generally required of employees of the Company, you shall
be entitled to participate in other employee benefit plans from time to time in effect for employees of the Company generally, including
without limitation, pension and/or profit-sharing plans.
(h) Business
Expenses. The Company shall pay or reimburse you for all reasonable and necessary business expenses incurred or paid by you in
the performance of your duties and responsibilities. Reimbursable expenses must be substantiated in writing (by valid receipts or
any other reasonable method of invoicing, showing proof of payment for an eligible reimbursement cost) within thirty (30) days of
the date any such expense is incurred. Any such expense will be reimbursed to you via check or electronic funds transfer by the
thirtieth (30th) day following the date of receipt by the Company of your written substantiation.
4. Confidential
Information; Assignment of Inventions.
(a) You
acknowledge that the Company and its Affiliates will continually develop Confidential Information (as defined below), that you may develop
Confidential Information for the Company or its Affiliates, and that you may learn of Confidential Information during the course of your
employment with the Company. You agree that, except as required for the proper performance of your duties for the Company, you will not,
directly or indirectly, use or disclose any Confidential Information. You understand and agree that this restriction will continue to
apply after your employment terminates, regardless of the reason for termination.
(b) You agree that all Confidential Information, including, without limitation all work products, inventions methods, processes, designs, software, apparatuses, compositions of matter, procedures, improvements, property, data documentation, information or materials that you, jointly or separately prepared, conceived, discovered, reduced to practice, developed or created during, in connection with, for the purpose of, related to, or as a result of your employment with the Company, and/or to which you have access as a result of your employment with the Company (collectively, “Inventions”) is and shall remain the sole and exclusive property of the Company.
(c) By signing this Letter you unconditionally and irrevocably transfer and assign to the Company all rights, title and interest in the Inventions (as defined above, including all patent, copyright, trade secret and any other intellectual property rights therein) and will take any steps and execute any further documentation from time to time reasonably necessary to effect such assignment free of charge to the Company. You will further execute, upon request, whether during, or after the termination of, your employment with the Company, any and all applications for patents, assignments and other papers, which the Company may deem necessary or appropriate for securing such Inventions for the Company.
(d) Except as required for the proper performance of your duties, you will not copy any and all papers, documents, drawings, systems, data bases, memoranda, notes, plans, records, reports files, data (including original data), disks, electronic media etc. containing Confidential Information (“Documents”) or remove any Documents, or copies, from Company premises. You will return to the Company immediately after your employment terminates, and at such other times as may be specified by the Company, all Documents and copies and all other property of the Company and its Affiliates then in his possession or control.
5. Conflicting
Agreements. You hereby represent and warrant that the execution of this Letter and the performance of his obligations hereunder will
not breach or be in conflict with any other agreement to which you are a party or are bound to and that you are not subject to any covenants
against competition or similar covenants that would affect the performance of your obligations hereunder. You will not disclose to or
use any confidential or proprietary information of a third party without such party’s consent.
6. Definitions.
Words or phrases which are initially capitalized or are within quotation marks shall have the meanings provided in this Section 6
and as provided elsewhere herein. For purposes of this Letter, the following definitions apply:
(a) “Affiliates”
means all persons and entities directly or indirectly controlling, controlled by or under common control with the Company, where control
may be by either management authority or equity interest.
(b) “Change
in Control Event” means either of the following: (i) sale of substantially all the Company’s assets or (ii) merger,
consolidation or reorganization resulting in a change in more than 50% of the board of directors combined with a transfer of majority
ownership or equity of the Company.
(c) “Confidential
Information” means any and all information, inventions, discoveries, ideas, writings, communications, research, engineering
methods, developments in chemistry, manufacturing information, practices, processes, systems, technical and scientific information, formulae,
designs, concepts, products, intellectual property, trade secrets, projects, improvements and developments that relate to the business
of the Company or any Affiliate and are not generally known by others, including but not limited to (i) products and services, technical
data, methods and processes, (ii) marketing activities and strategic plans, (iii) financial information, costs and sources of
supply, (iv) the identity and special needs of customers and prospective customers and vendors and prospective vendors, and (v) the
people and organizations with whom the Company or any Affiliate has or plans to have business relationships and those relationships. Confidential
Information also includes such information that the Company or any Affiliate may receive or has received belonging to customers or others
who do business with the Company or any Affiliate and any publication or literary creation of yours, developed in whole or in part while
you are employed by the Company, in whatever form published the content of which, in whole or in part, relates to the business of the
Company or any Affiliate. Confidential Information shall not include any information or materials that you can prove by written evidence
(i) is or becomes publicly known through lawful means and without breach of this Letter by you; (ii) was rightfully in your
possession or part of your general knowledge prior to the Effective Date; or (iii) is disclosed to you without confidential or proprietary
restrictions by a third party who rightfully possesses the information or materials without confidential or proprietary restrictions.
(d) “Good
Reason” means a material reduction in your duties or material reduction in compensation, except for a reduction in compensation
that affects all members of management on the same percentage basis.
(c) “Person”
means an individual, a corporation, an association, a partnership, an estate, a trust and any other entity or organization.
7. Withholding.
All payments made under this Letter shall be reduced by any tax or other amounts required to be withheld under applicable law.
8. Severability.
If any portion or provision of this Letter shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction,
then the remainder of this Letter, or the application of such portion or provision in circumstances other than those as to which it is
so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Letter shall be valid and
enforceable to the fullest extent permitted by law.
9. Waiver.
No waiver of any provision hereof shall be effective unless made in writing and signed by the waiving party. The failure of either party
to require the performance of any term or obligation of this Letter, or the waiver by either party of any breach of this Letter, shall
not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent breach.
10. Notices.
Any and all notices, requests, demands and other communications provided for by this Letter shall be in writing and shall be effective
when delivered in person or by overnight courier or delivery service, or 3 business days after being deposited in the United States mail,
postage prepaid, registered or certified, and addressed to you at your last known address on the books of the Company or, in the case
of the Company, at the Company’s principal place of business, to the attention of the Chief Executive Officer, or to such other
address as either party may specify by notice to the other actually received.
11. Entire
Letter. This Letter constitutes the entire Letter between the parties and supersedes all prior communications, agreements and understandings,
written or oral, with respect to the terms and conditions of your employment.
12. Amendment.
This Letter may be amended or modified only by a written instrument signed by you and an expressly authorized representative of the Company.
13. Headings.
The headings and captions in this Letter are for convenience only and in no way define or describe the scope or content of any provision
of this Letter.
14. Counterparts.
This Letter may be executed in two or more counterparts, each of which shall be an original and all of which together shall constitute
one and the same instrument.
15. Governing
Law. This Letter shall be construed and enforced under and be governed in all respects by the laws of the State of California, without
regard to the conflict of laws principles thereof.
Daron, we look forward to you joining the Rezolute
team!
Sincerely,
Rezolute, Inc.
Nevan Elam
Chief Executive Officer
Agreed and accepted:
Daron Evans
Date: January 23, 2024
Exhibit 99.1
Rezolute Receives Innovation
Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due
to Congenital Hyperinsulinism
REDWOOD
CITY, Calif., January 23, 2024 -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical
company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced that the
U.K. Medicines and Healthcare products Regulatory Agency (MHRA) has awarded the innovative medicine designation, the Innovation Passport,
to RZ358 for the treatment of hypoglycemia due to congenital hyperinsulinism (HI). The Innovation Passport designation was granted
based on the substantial unmet medical need in this condition and the potential for RZ358 to benefit patients as evidenced by the Phase
2 RIZE study in congenital HI, which safely demonstrated significant improvements in hypoglycemia events.
The
Innovation Passport designation in the U.K. is the entry point to the Innovative Licensing and Access Pathway (ILAP). The goal of ILAP
is to accelerate the time to market and facilitate patient access to medicines. The Innovation Passport is the first step in the
ILAP process, which activates the Medicines and Healthcare products Regulatory Agency (MHRA) and its partner agencies, including the National
Institute for Health and Care Excellence (NICE), and the Scottish Medicines Consortium (SMC).
“Congenital
hyperinsulinism is the most frequent cause of severe, persistent hypoglycemia in newborn babies, infants and children,” said Susan
Stewart, J.D., Chief Regulatory Officer at Rezolute. “The Innovation Passport opens the door for Rezolute to discuss access considerations
for potential future indications for RZ358. We are thrilled to receive this designation and work closely with the U.K. and other regulatory
authorities to bring this meaningful therapy to patients in need.”
About Congenital Hyperinsulinism
Congenital hyperinsulinism (congenital
HI) is the most common cause of recurrent and persistent hypoglycemia in children. Patients with congenital HI typically present with
signs or symptoms of hypoglycemia within the first month of life. These episodes can result in significant brain injury and death if not
recognized and managed appropriately. Additionally, recurrent, or cumulative, hypoglycemia can lead to progressive and irreversible damage
over time, including serious and devastating brain injury, seizures, neuro-developmental problems, feeding difficulties, and significant
impact on patient and family quality of life. In cases of congenital HI that are unresponsive to medical management, surgical removal
of the pancreas may be required. In those with diffuse congenital HI where the whole pancreas is affected, a near-total pancreatectomy
can be undertaken, although about half of these children will continue to have hypoglycemia and require medical treatment for congenital
HI.
About RZ358
RZ358 is a fully human monoclonal
antibody that works downstream from the pancreas and instead binds to a unique allosteric site on insulin receptors in the liver, fat,
and muscle. The antibody counteracts the effects of excess insulin binding and activity, thereby improving hypoglycemia. Rezolute believes
that RZ358 is ideally suited as a potential therapy for congenital HI and other conditions characterized by excessive insulin activity
(hyperinsulinism). Because RZ358 acts downstream from the pancreas, it has the potential to be universally effective at treating congenital
HI, regardless of the causative genetic defect, as well as acquired forms of HI such as those mediated by insulinomas and other tumor
types. RZ358 received Orphan Drug Designation in the United States and European Union for the treatment of congenital HI, as well as
Pediatric Rare Disease Designation in the U.S. In the Phase 2 RIZE study, participants with congenital HI ages 2 and older nearly universally
achieved significant improvements in hypoglycemia across multiple endpoints, including the primary and key secondary endpoints planned
for the sunRIZE study. At doses and exposures that are planned for the Phase 3 study, RZ358 was generally safe and well-tolerated, and
resulted in median improvements in hypoglycemia exceeding 80%. Based on the RIZE clinical trial outcomes and the evidence of benefit
in this serious condition with substantial unmet medical need, RZ358 was subsequently granted a priority medicines (PRIME) designation
by the European Medicines Agency (EMA) and an Innovation Passport designation by the U.K. Innovative Licensing and Access Pathway (ILAP)
Steering Group for the treatment of congenital HI.
About Rezolute, Inc.
Rezolute
strives to disrupt current treatment paradigms by developing transformative therapies for devastating rare and chronic metabolic diseases.
Its novel therapies hold the potential to both significantly improve outcomes and reduce the treatment burden for patients, treating
physicians, and the healthcare system. Rezolute is steadfast in its mission to create profound, positive, and lasting impacts on patients’
lives. Patient, clinician, and advocate voices are integrated in the Company’s drug development process. Rezolute places an emphasis
on understanding the patient’s lived experiences, enabling the Company to boldly address a range of severe conditions. For more
information, visit www.rezolutebio.com.
Forward-Looking Statements
This release, like many written
and oral communications presented by Rezolute and our authorized officers, may contain certain forward-looking statements regarding our
prospective performance and strategies within the meaning of Section 27A of the Securities Act and Section 21E of the Securities
Exchange Act of 1934, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking
statements contained in the Private Securities Litigation Reform Act of 1995 and are including this statement for purposes of said safe
harbor provisions. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations
of Rezolute, are generally identified by use of words such as "anticipate," "believe," "estimate," "expect,"
"intend," "plan," "project," "seek," "strive," "try," or future or conditional
verbs such as "could," "may," "should," "will," "would," or similar expressions. These forward-looking statements include,
but are not limited to statements regarding the Innovation Passport designation, the PRIME designation and the meaning of the designations
on the ability of RZ358 to become an effective treatment for congenital hyperinsulinism, the effectiveness or future effectiveness of
RZ358 for the treatment of congenital hyperinsulinism, and statements regarding clinical trial timelines for RZ358. Our ability to predict
results or the actual effects of our plans or strategies is inherently uncertain. Accordingly, actual results may differ materially from
anticipated results. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the
date of this release. Except as required by applicable law or regulation, Rezolute undertakes no obligation to update these forward-looking
statements to reflect events or circumstances that occur after the date on which such statements were made. Important factors that may
cause such a difference include any other factors discussed in our filings with the SEC, including the Risk Factors contained in the
Rezolute’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, which are available at the SEC’s website
at www.sec.gov. You are urged to consider these factors carefully in evaluating the forward-looking statements in this release and are
cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement.
Investors &
Media:
Christen Baglaneas
Rezolute, Inc.
cbaglaneas@rezolutebio.com
(508)272-6717
Investors:
Stephanie Carrington
ICR Westwicke
RezoluteIR@westwicke.com
(646)277-1282
Exhibit 99.2
Rezolute Expands Leadership
Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer
REDWOOD
CITY, Calif., January 24, 2024 -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical
company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced the addition
of Daron Evans, MS, MBA, to its leadership team as Chief Financial Officer as well as the grant of share options as a material inducement
for his appointment (the “Inducement Grant”).
About
Mr. Evans
“This
is a pivotal year for Rezolute as we initiated our Phase 3 clinical study for RZ358 in congenital hyperinsulinism and anticipate reporting
topline data from our Phase 2 study for RZ402 in diabetic macular edema in the second quarter of 2024,” said Nevan Charles Elam,
Chief Executive Officer and Founder of Rezolute. “As a seasoned biotech leader and entrepreneur, Mr. Evans has recognized the
value of our novel therapies for rare and metabolic disease. His experience in corporate finance, capital markets, and strategic transactions
will help shepherd Rezolute through its next chapter in late-stage development and support its mission to help patients in need.”
Mr. Evans
has over 15 years of experience leading public and private life science companies through financial operations, investor relations, and
business development activities. Prior to joining Rezolute, he served as Chief Executive Officer of AlloRock, Inc., a biotechnology
company in the cardiometabolic disease space, as well as Chief Executive Officer of Specialty Renal Products, Inc., a medical device
company in the dialysis space. Previously, Mr. Evans served as Chief Executive Officer of Nephros, Inc. (Nasdaq:NEPH), and Chief
Financial Officer of Nile Therapeutics, Inc. (Nasdaq:NLTX). Since 2015, Mr. Evans has been Managing Director of PoC Capital,
LLC, a fund focused on investing in public life science companies. He holds a Bachelor of Science in Chemical Engineering from Rice University,
a Master of Science in Biomedical Engineering from a joint program at the University of Texas at Arlington and Southwestern Medical School,
and a Master of Business Administration from the Fuqua School of Business at Duke University.
“Rezolute
is on the precipice of potentially making a significant impact on the lives of patients and their families in multiple indications,”
said Mr. Evans. “I am very impressed with the dedication and experience of the Rezolute team and am honored to join the mission
at this critical time.”
Inducement
Grant
In connection
with Mr. Evans’ appointment, on January 23, 2024, the Company’s Board of Directors, upon recommendation of the Compensation
Committee, approved the grant of an inducement stock option of 275,000 shares of the Company’s common stock in accordance with Nasdaq
Listing Rule 5635(c)(4). The option has an exercise price of $1.02 per share, which is equal to the closing price of Rezolute’s
common stock on January 23, 2024. The stock options will vest and become exercisable as to 25% of the underlying shares on the first
anniversary of the grant date, and will vest and become exercisable as to the remaining 75% of the underlying shares in 36 equal monthly
installments from the first anniversary of the grant date, subject to his continued employment with Rezolute on such vesting dates. If
the Company is acquired during his employment, all remaining options will automatically vest.
About Rezolute, Inc.
Rezolute
strives to disrupt current treatment paradigms by developing transformative therapies for devastating rare and chronic metabolic diseases.
Its novel therapies hold the potential to both significantly improve outcomes and reduce the treatment burden for patients, treating
physicians, and the healthcare system. Rezolute is steadfast in its mission to create profound, positive, and lasting impacts on patients’
lives. Patient, clinician, and advocate voices are integrated in the Company’s drug development process. Rezolute places an emphasis
on understanding the patient’s lived experiences, enabling the Company to boldly address a range of severe conditions. For more
information, visit www.rezolutebio.com.
Forward-Looking Statements
This release, like many written
and oral communications presented by Rezolute and our authorized officers, may contain certain forward-looking statements regarding our
prospective performance and strategies within the meaning of Section 27A of the Securities Act and Section 21E of the Securities
Exchange Act of 1934, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking
statements contained in the Private Securities Litigation Reform Act of 1995 and are including this statement for purposes of said safe
harbor provisions. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations
of Rezolute, are generally identified by use of words such as "anticipate," "believe," "estimate," "expect,"
"intend," "plan," "project," "seek," "strive," "try," or future or conditional
verbs such as "could," "may," "should," "will," "would," or similar expressions. These forward-looking statements include,
but are not limited to statements regarding the appointment of Daron Evans as Chief Financial Officer, the Inducement Grant for Daron
Evans’ appointment, the Innovation Passport designation, the PRIME designation and the meaning of the designations on the ability
of RZ358 to become an effective treatment for congenital hyperinsulinism, the effectiveness or future effectiveness of RZ358 for the treatment
of congenital hyperinsulinism, and statements regarding clinical trial timelines for RZ358. Our ability to predict results or the actual
effects of our plans or strategies is inherently uncertain. Accordingly, actual results may differ materially from anticipated results.
Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release.
Except as required by applicable law or regulation, Rezolute undertakes no obligation to update these forward-looking statements to reflect
events or circumstances that occur after the date on which such statements were made. Important factors that may cause such a difference
include any other factors discussed in our filings with the SEC, including the Risk Factors contained in the Rezolute’s Annual Report
on Form 10-K and Quarterly Reports on Form 10-Q, which are available at the SEC’s website at www.sec.gov. You are urged
to consider these factors carefully in evaluating the forward-looking statements in this release and are cautioned not to place undue
reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement.
Investors &
Media:
Christen Baglaneas
Rezolute, Inc.
cbaglaneas@rezolutebio.com
(508)272-6717
Investors:
Stephanie Carrington
ICR Westwicke
RezoluteIR@westwicke.com
(646)277-1282
v3.24.0.1
Cover
|
Jan. 23, 2024 |
Cover [Abstract] |
|
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Jan. 23, 2024
|
Entity File Number |
001-39683
|
Entity Registrant Name |
REZOLUTE, INC.
|
Entity Central Index Key |
0001509261
|
Entity Tax Identification Number |
27-3440894
|
Entity Incorporation, State or Country Code |
NV
|
Entity Address, Address Line One |
275 Shoreline Drive
|
Entity Address, Address Line Two |
Suite 500
|
Entity Address, City or Town |
Redwood City
|
Entity Address, State or Province |
CA
|
Entity Address, Postal Zip Code |
94065
|
City Area Code |
650
|
Local Phone Number |
206-4507
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Title of 12(b) Security |
Common Stock, par value $0.001 per share
|
Trading Symbol |
RZLT
|
Security Exchange Name |
NASDAQ
|
Entity Emerging Growth Company |
false
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Rezolute (NASDAQ:RZLT)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Rezolute (NASDAQ:RZLT)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024